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Abstract: Indiplon is a novel pyrazolopyrimidine, nonbenzodiazepine γ-aminobutyric acid 
(GABA) agonist studied for the treatment of insomnia. This article reviews the chemistry, 
pharmacology, clinical pharmacokinetics, drug interactions, clinical trials, safety, tolerability, 
contraindications, use in special populations, and dosing of indiplon. OVID, International 
Pharmaceutical Abstracts (IPA), and PubMed databases were searched (1966 to February 2009) 
for the keywords indiplon, NBI-34060, and insomnia. References of key articles were also 
reviewed to identify additional publications. Only English language articles were selected for 
review. Indiplon has been shown to have high affinity and selectivity for the GABAα1 recep-
tor subunit associated with sedation. In clinical studies, indiplon has demonstrated efficacy in 
improving latency to sleep onset, latency to persistent sleep, total sleep time, wake time after 
sleep onset, number of awakenings after sleep onset, and overall sleep quality when compared 
to placebo. Indiplon has a favorable safety profile with limited rebound insomnia and no toler-
ance. Neurocrine Biosciences, Incorporated received an Approvable Letter from the United 
States Food and Drug Administration in December 2007 for the indiplon IR 5 mg and 10 mg 
capsules based on meeting three additional requirements. At the time of this writing, indiplon 
remains unapproved.
Keywords: indiplon, insomnia, NBI-34060
Introduction
The diagnostic criteria for primary insomnia, from the Diagnostic and Statistical 
Manual of Mental Disorders fourth edition, text revision (DSM-IV-TR), includes 
difficulty falling asleep, intermittent wakefulness during sleep and/or nonrestorative 
sleep (poor quality sleep) for at least one month.1 From the 2005 Sleep in America 
Poll, the symptoms reported at least a few nights a week with insomnia were waking 
up feeling unrefreshed (38%), awake a lot at night (32%), difficulty falling asleep 
(21%), and woke up too early and could not get back to sleep (21%).2 Clinically, 
patients can be impacted in their social and occupational functioning. Daytime 
consequences such as fatigue, decreased attention, decreased energy, along with lack 
of motivation, and deteriorated mood may occur. Approximately one-third of adult 
Americans experience symptoms of insomnia intermittently, while 10%–15% report 
having chronic insomnia.3,4
Treatment options for insomnia include cognitive behavioral therapy and/or 
pharmacologic therapy.5–7 The pharmacologic classes prescribed for insomnia include 
benzodiazepines, nonbenzodiazepine sedative hypnotics, melatonin receptor agonists, 
antidepressants with sedating properties, and sedating antihistamines. Indiplon is a Drug Design, Development and Therapy 2009:3 132
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nonbenzodiazepine sedative hypnotic with more selectivity 
for γ-aminobutyric acid (GABA) receptors with the α1 
subunit.8,9
Neurocrine Biosciences, Incorporated (Inc) (San Diego, 
CA, USA) has researched immediate (IR) and modified 
release (MR) formulations of indiplon. On May 15, 2006, 
the US Food and Drug Administration (FDA) granted an 
Approvable Letter for indiplon IR 5 mg and 10 mg capsules.10 
The FDA also requested a reanalysis of certain study data to 
support the indications of sleep initiation and middle of the 
night dosing, a reanalysis of safety data for the elderly, and a 
supplemental pharmacokinetic/food effect trial. A New Drug 
Application for indiplon IR was resubmitted to the FDA on 
June 12, 2007. Indiplon IR received an Approvable Letter 
from the FDA in December 2007 for the 5 mg and 10 mg 
dosage forms based on meeting three additional require-
ments. The FDA requested a study in elderly patients, a study 
comparing adverse events of indiplon versus an approved 
product for the treatment of insomnia, and a preclinical 
study to evaluate its use in the third trimester of pregnancy. 
According to the Neurocrine Biosciences, Inc 2008 fourth 
quarter report, a meeting with the FDA occurred in July 
2008 and the company is awaiting a final version of those 
minutes to determine the next step with indiplon.11 Currently 
indiplon is not reported as being approved for use in any 
other countries.10
Indiplon MR 15 mg tablets received a Not Approvable 
Letter in May 2006.10 The not approvable status involved 
indiplon MR doses 15 mg/d and insufficient sleep main-
tenance data. The FDA requested a long-term safety and 
efficacy trial for adults and the development of a separate 
MR dose for the elderly. At this time, the MR 15 mg dose 
has not been resubmitted to the FDA.
This review will focus on the chemistry, pharmacology, 
clinical pharmacokinetics, drug interactions, clinical trials, 
adverse reactions, contraindications, use in special popula-
tions, and dosing of indiplon in the treatment of primary 
insomnia.
Chemistry and pharmacology
The GABAA receptor is a pentameric molecule composed 
of a combination of one or more specific subunit types. 
Although 19 different subunits are known to exist,12 the 
majority of GABAA receptors in the central nervous 
system consist of α(1–6), β(1–3), and γ(1–3) subunits.13 The 
interaction of benzodiazepines with multiple GABAA 
receptor subunits containing α(1–3,5) is thought to elicit the 
variety of effects seen with these agents such as anxiolysis, 
amnesia, muscle relaxation, sedation, and anticonvulsant 
activity.13,14 The α1-receptor subunit has been associated 
with inducing sedation.13,14 The theoretical advantage 
of having a selective α1 subunit agonist is that sedating 
effects are achieved while avoiding other effects thought 
to be mediated by the other α subunits to which benzo-
diazepines bind.
In contrast to benzodiazepines, the nonbenzodiazepine 
sedative hypnotics (ie, zolpidem, eszopiclone, zopiclone, 
zaleplon) are more selective for the GABAA receptors with 
the α1-receptor subunit.8 Indiplon, a new pyrazolopyrimidine 
sedative hypnotic, has been shown to have high affinity and 
selectivity for the α1 subunit associated with sedation.8,9 
Petroski and colleagues15 showed indiplon to be at least 
nine times more selective for α1 as compared to α2, α3, and 
α5 subunits.15 This study further showed that the degree of 
selectivity for α1, over the α2 and α3 subunits, was greater 
for indiplon as compared to zolpidem, zopiclone, and 
zaleplon. The α2 subunit is involved in producing anxiolytic 
effects.13 The 9.3 times lower affinity of indiplon to the α2 
vs α1 subunit suggests it does not have significant anxiolytic 
properties.15
Continual use of benzodiazepines such as triazolam has 
been associated with the development of tolerance during 
intermediate and long-term use.16 Although tolerance 
has been reported less with agents such as zolpidem,16 it 
remains important to evaluate these parameters for agents 
used for inducing sleep. Jochelson and colleagues17 studied 
30 healthy males, aged 22–41, to identify pharmacokinetic or 
pharmacodynamic tolerance associated with indiplon. Study 
subjects were prescribed indiplon 10 mg, 30 mg, or 45 mg 
once daily for 14 consecutive days. The pharmacokinetic 
and pharmacodynamic analysis showed similar results on 
day 1 as compared to day 14 concluding no tolerance was 
associated with indiplon. Moscovitch and colleagues18 also 
reported no evidence of tolerance in a six-month elderly 
study. The mean number of indiplon IR doses throughout 
the study was 22 per month. Indiplon’s high selectivity for 
the α1-subunit, as well as a short half-life may theoretically 
contribute to its lack of tolerance.15
Clinical pharmacokinetics
Indiplon is extensively metabolized in the liver to two 
major inactive metabolites.19 The CYP3A4/5 enzyme 
primarily accounts for the formation of N-desmethyl-
indiplon (60%–70%) while carboxylesterase enzymes form 
N-desacetyl indiplon (30%–40%). A secondary inactive 
metabolite, N-desmethyl-N-desacetyl-indiplon, is produced Drug Design, Development and Therapy 2009:3 133
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by the N-demethylation of N-desacetyl-indiplon as well 
as the N-deacetylation of N-desmethyl-indiplon. Less 
than 1% of indiplon is eliminated in the urine or feces as 
unchanged drug.
Animal data show indiplon attains a peak plasma level 
(Tmax) in 30 minutes and has a half-life of 60 minutes.8 
A human trial by Rogowski and colleagues20 administered 
indiplon IR 15 mg orally to all subjects and revealed the 
Tmax in males was 0.73 hours with a half-life of 1.97 hours. 
In female subjects, the Tmax was 0.82 hours with a half-life 
of 1.71 hours. Although this trial included only 24 subjects, 
no statistically significant gender differences were found 
in regards to indiplon’s pharmacokinetics. Jochelson and 
colleagues21 evaluated 12 adults aged 18–45 and compared 
them to 13 elderly subjects aged 65–79. After one oral dose 
of indiplon IR 15 mg, the mean Tmax in the younger adult 
population was 2.3 hours compared to 2.7 hours in the 
elderly group. The mean half-life of indiplon was 1.5 hours 
in the young adults and 1.8 hours in the elderly group. 
Statistical evaluation of this data determined no significant 
differences exist between the young and elderly populations. 
This study included similar numbers of males and females 
in each group and also determined no differences in gender 
exist in regards to indiplon pharmacokinetics. The carbo-
xylesterase metabolic pathway, which is less affected by 
age and not known to have gender differences, is one of the 
proposed reasons for similar pharmacokinetics seen across 
these populations.20,21 A trial by Bozigian and colleagues22 
further evaluated the pharmacokinetics of indiplon 10 mg, 
15 mg, 20 mg, and 30 mg daily in 24 young healthy males. 
A dose-dependent linear increase in area under the curve 
(AUC) as well as a proportional dose-dependent increase 
in maximum concentration was evident. The Tmax was 
about one hour for all doses and the half-life varied from 
2.59–3.82 hours.
Drug interactions
Ketoconazole, troleandomycin, and erythromycin are 
inhibitors of the CYP3A4 enzyme and have been shown 
to decrease the metabolism of indiplon.19 Ketoconazole 
increased the plasma AUC by 2.4-fold while erythromy-
cin increased indiplon’s plasma AUC by 1.25-fold. The 
alternative route of carboxylesterase metabolism may explain 
why the change in plasma AUC due to a highly potent 
inhibitor like ketoconazole is limited to a 2.4-fold increase. 
Indiplon was also studied in conjunction with sertraline and 
paroxetine and no changes in indiplon pharmacokinetics 
were seen, nor were there any pharmacodynamic changes 
in regards to tests of psychomotor function and alertness.23 
Concomitant use of rifampin, a CYP3A4 inducer, has been 
shown to reduce the plasma AUC of indiplon by 70%.19
Indiplon is a weak inhibitor of CYP450 enzymes, and is 
not expected to cause any clinically significant inhibition of 
other medications.19 Abel and colleagues24 studied indiplon 
use in conjunction with aminophylline, digoxin, and warfarin 
and revealed indiplon did not affect the pharmacokinetics 
of any of the drugs studied. Indiplon does not induce the 
CYP1A2 or CYP3A4 enzymes and thus is not expected to 
cause any significant interaction through enzyme induction.19 
Interactions with the carboxylesterase metabolism pathway 
are not expected, as no currently marketed drugs are known 
to inhibit these enzymes.
Berkowitz and colleagues25 studied the interaction of 
ethanol with indiplon. Ten male subjects were randomized 
to indiplon 10 mg, ethanol 0.7 mg/ml, or both. Indiplon’s 
peak plasma level at one hour and half-life were not affected 
by ethanol. The Digital Symbol Substitution Test (DSST) 
and Symbol Copying Test (SCT) were utilized to evaluate 
performance. DSST involves measuring cognitive function 
by giving a subject 90 seconds to use a nine digit code key 
and substitute the correct symbol for each digit shown on the 
test.26 A lower score on the DSST indicates more impairment. 
The SCT assesses the motor component of the DSST by 
asking the subject to copy the same numbers used in the 
DSST. Based on the DSST and SCT, a slight decrease in 
performance was evident when indiplon and ethanol were 
combined, however no effect on sedation or reaction time 
was seen.25 Different metabolic pathways easily explain the 
lack of pharmacokinetic interaction, however the minimal 
pharmacodynamic interaction is not as well defined. The 
lack of interaction of indiplon with the α2 subunit has been 
proposed as a possible reason for the lack of a pharmacody-
namic interaction with ethanol.15
Clinical studies
Indiplon IR efficacy and safety was evaluated in 10 random-
ized, double-blind, placebo controlled trials,26–33 and one 
open label extension trial.18 The efficacy of indiplon MR 
was evaluated in four randomized, double-blind, placebo 
controlled trials.34–37 Trial data is summarized in Table 126–31 
for indiplon IR in adults, Table 218,26,32,33 for indiplon IR in the 
elderly, and Table 334–37 for indiplon MR. Table 4 provides a 
summary of the clinical efficacy terms used in the indiplon 
studies.38–40 It should be noted that Neurocrine Biosciences, 
Inc sponsored all the studies and many of the studies are only 
available in abstract form.Drug Design, Development and Therapy 2009:3 134
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immediate release indiplon
Adult studies
Efficacy of indiplon IR was evaluated in patients meeting 
DSM-IV criteria for primary insomnia with nocturnal 
awakenings.27 Patients received indiplon IR 10 mg, 20 mg, 
or placebo. This was a post-bedtime dose study and most 
patients took the medication between the hours of 12:00 AM 
and 2:00 AM. The mean number of doses taken per week 
was 3.9 ± 1.9, 3.7 ± 1.7, and 3.7 ± 1.9 for the 10 mg, 20 mg, 
and placebo groups, respectively. All study outcomes were 
subjectively measured. The primary outcome was patient 
rated latency to sleep onset (LSO) post-dose in which the four-
week average was decreased to mean ± standard error of mean 
(SEM) values of 36.5 ± 1.8 minutes (p = 0.0023) in the 10 mg 
group, 34.4 ± 1.7 minutes (p  0.0001) in the 20 mg group, 
and 45.2 ± 2.2 minutes in the placebo group. Average total 
sleep time (TST) improved significantly at 253 ± 6.8 minutes 
in the 10 mg group (p = 0.0099) and 278 ± 6.5 minutes in the 
20 mg group (p  0.0001), compared to 229 ± 6.6 minutes 
in the placebo group. Baseline values for the wake time after 
sleep onset (WASO) were 27.5 ± 4.6 minutes for the placebo 
group, 31.7 ± 4.7 minutes for the 10 mg group, and 37.7 ± 4.6 
minutes for the 20 mg group. Only in the 20 mg group was 
the four-week average WASO significant with values of 
24.4 ± 3.5, 16.2 ± 3.6, and 12 ± 3.5 minutes (p = 0.0122) 
in the placebo, 10 mg, and 20 mg groups, respectively. The 
number of awakenings after sleep-onset (NAASO) was 
significantly reduced only in the 20 mg group (p = 0.0125). 
Overall sleep quality was improved in both indiplon treatment 
groups compared to placebo (10 mg, p = 0.0007 and 20 mg, 
p  0.0001). Next day residual effects as rated on the Visual 
Analog Scale for sleepiness (VAS-S) were significantly better 
for both the 10 mg and 20 mg groups as indicated by a 10 mm 
or greater improvement in the VAS-S for next day alertness 
compared to placebo (p  0.05). VAS-S is a scale where 
study subjects rate their level of alertness or sleepiness on a 
VAS which ranges from very alert to very sleepy.
Walsh and colleagues28 examined indiplon IR 10 mg or 
20 mg versus placebo over five weeks in patients with primary 
insomnia of at least three months duration. Results from 
week 1 for polysomnography (PSG) measuring latency to 
persistent sleep (LPS) demonstrated significant improvement 
in the 10 mg and 20 mg groups versus placebo. The values 
for LPS at week 1 were 27.7 minutes for the 10 mg group 
(p  0.01) and 27.1 minutes for the 20 mg group (p  0.05), 
in contrast to 36.9 minutes for the placebo group. At week 5 
of the study, LPS values remained significant at 29.2 minutes 
(p  0.01) for the 10 mg group and 24.8 minutes (p  0.05) 
for the 20 mg group, versus 40.1 minutes in the placebo 
group. TST (no values reported) was significantly better than 
placebo only during week 1 in the 10 mg group (p  0.02). 
At week 1, the LSO was significantly reduced compared to 
placebo with values of 49.8 (p  0.0001), 44.4 (p  0.003), 
and 72.5 minutes in the indiplon 10 mg, 20 mg, and placebo 
groups, respectively. The LSO remained significantly better 
than placebo in both active treatments at week 5 (p  0.02; 
no values reported). Sleep quality was only significantly 
better during week 1 in the 10 mg and 20 mg groups versus 
Table 1 Clinical efficacy trials of indiplon IR in adults
Author (year) N Age range  
in years (Mean)
Duration Dose (mg) Outcomes
Farber (2008)26 35 18–45 (32.4) One night  
per arm
indiplon 10, 20 placebo  
zolpidem 10 zopiclone 7.5
No change in DSST, SCT,    vAS-S for indiplon at 
4 and 6 hours post-dose. ↑ vAS-S for zolpidem 
at 4 hours. ↑ vAS-S for zopiclone at 4 and 
6 hours. No change in DSST and SCT for 
zolpidem and zopiclone at 4 and 6 hours.
roth (2007)27 264 18–64 (46) Four weeks indiplon 10, 20 placebo ↓ LSOc, ↓ swASO (20 mg only), ↓ sNAASO 
(20 mg only), ↑ sTST, ↑ sleep quality
walsha (2004)28 194 range Nr (40.2) Five weeks indiplon 10, 20 placebo ↓ LPS, ↓ sLSO, ↑ TST (10 mg, week 1 only),  
↑ sleep quality (week 1 only)
rosenberg (2007)29 593 21–64 (32) One night indiplon 10, 20 placebo ↓ LPSc, ↑ TST, ↓ NAASO (20 mg only),  
↓ wASO (20 mg only), ↑ sleep quality
rotha (2003)30 228 18–59 (Nr) One night indiplon 15b, 30b placebo ↓ LPS, ↓ LSO, No change TST
Scharf (2007)31 702 21–64 (46) Three months indiplon 10, 20 placebo ↓ sLSOc, ↑ sTST, ↓ swASO, ↓ sNAASO,  
↑ sleep quality
Notes: aAbstract-only data; bsolution; cdesignated as primary endpoint.
Abbreviations: DSST, digit symbol substitution test; LSO, latency to sleep onset; LPS, latency to persistent sleep; NAASO, number of awakenings after sleep onset; Nr, not 
reported; s, subjective or self; SCT, symbol copying test; TST, total sleep time; vAS-S, visual analog scale of sleepiness; wASO, wake after sleep onset.Drug Design, Development and Therapy 2009:3 135
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placebo (p  0.03; no values reported). No difference in 
next day residual effects was noted between the placebo and 
indiplon groups.
The efficacy of indiplon was also examined in two studies 
using a transient model of insomnia.29,30 The first study 
evaluated the efficacy of indiplon IR 10 mg and 20 mg doses 
in healthy volunteers using an experimental model of transient 
insomnia induced by sleeping in an unfamiliar place and a two-
hour earlier bedtime.29 LPS values as measured by PSG were 
significantly decreased in the 10 mg group to 21.2 ± 1.5 minutes 
and in the 20 mg group to 16.8 ± 1.1 minutes, compared to 
the placebo group at 33.1 ± 2.5 minutes (p  0.0001). TST 
as measured by PSG was significantly increased in both the 
10 mg and 20 mg groups compared to placebo with mean 
values of 414.5 ± 3.9 minutes (p = 0.0044), 423.5 ± 3.1 minutes 
(p  0.0001), and 402.9 ± 3.9 minutes, respectively. NAASO 
as measured by PSG was significantly decreased only in the 
20 mg group and the median values were 7 in the 10 mg group 
(p = 0.0583), 6 in the 20 mg group (p = 0.0084), and 8 in the 
placebo group. WASO as measured by PSG was signifi-
cantly decreased only in the 20 mg group with mean values of 
49.9 ± 2.9 in the placebo group, 48.7 ± 3.5 (p = 0.2540) in the 
10 mg group, and 42.5 ± 2.8 minutes (p = 0.0091) in the 20 mg 
group. Subjective sleep quality was significantly improved 
in both the 10 mg (p = 0.0182) and 20 mg groups compared 
to placebo (p  0.0001). No differences in next day residual 
effects were noted in either treatment group versus placebo. The 
second study which used the experimental transient insomnia 
regimen included healthy volunteers using indiplon 15 mg 
or 30 mg solution, versus placebo.30 PSG measured LPS was 
significantly decreased with mean values of 17.5 minutes in the 
15 mg group and 16.2 minutes in the 30 mg group, compared 
to 34.1 minutes for placebo (p  0.001). Significant improve-
ment in subjective LSO was also noted with mean values of 
15.8, 15.4, and 31.1 minutes for the 15 mg, 30 mg, and placebo 
groups, respectively (p  0.001). No improvement in the PSG, 
TST, or subjectively measured TST was found in the indiplon 
groups versus placebo. Evaluation of next day effects found no 
difference between the indiplon and placebo groups.
Only one study has examined the long-term efficacy of 
indiplon. Scharf and colleagues31 evaluated indiplon IR 10 mg, 
20 mg, or placebo in patients who met DSM-IV criteria for 
primary insomnia of at least three months duration. In the 
three-month study, all of the primary and secondary outcomes 
were subjectively measured through patient sleep diaries. 
At one month, mean LSO was significantly improved to 
34 ± 1.3 minutes for 10 mg (p  0.0001) and 33.0 ± 1.3 minutes 
for 20 mg (p  0.0001), compared to 48.7 ± 1.9 minutes 
for placebo. Significant efficacy was maintained for all 
three months for LSO in the active treatment groups com-
pared to placebo. Mean TST was 327.5 ± 4 minutes at one 
month in the placebo group compared to 362.8 ± 3.9 minutes 
(p  0.0001) in the 10 mg group, and 372.1 ± 4 minutes 
(p  0.0001) in the 20 mg group, and efficacy was statisti-
cally maintained for three months. WASO was 61.1 ± 2.5, 
49.7 ± 2.4 (p = 0.0009), and 42.2 ± 2.5 minutes (p  0.0001) 
in the placebo, 10 mg, and 20 mg groups, respectively at one 
month and this efficacy was maintained for the three-month 
Table 2 Clinical efficacy trials of indiplon IR in the elderly
Author (year) N Age range  
in years (Mean)
Duration Dose (mg) Outcomes
walsh (2007)32 358 65–80 (71) Two weeks indiplon 5, 10 placebo ↓ sLSO, ↑ sTST, ↓ swASO 
(except 5 mg at week 1), 
↓ sNAASO, ↑ sleep quality
Moscovitcha (2006)18 121 65–80 (71) Six months indiplon 5, 10 Self-reported insomnia 
improvement: 72% (5 mg) 92% 
(10 mg)
Scharfa (2003)33 42 65–82 (70) Two nights per arm indiplon 5, 10, 20 placebo ↓ LPS, ↓ sLSO, ↑ TST  
(10, 20 mg only)
Farber (2008)26 36 65–80 (68.6) One night per arm indiplon 5, 10 placebo 
zopiclone 3.75
No change in vAS-S or SCT 
for all indiplon treatments. No 
change in DSST for indiplon 5 mg. 
↓ DSST for indiplon 10 mg at 4 h, 
but not at 6 and 8 hours. ↓ DSST 
for zopiclone at 4 and 8 hours, 
but not at 6 hours.
Note: aAbstract-only data.
Abbreviations: DSST, digit symbol substitution test; LSO, latency to sleep onset; LPS, latency to persistent sleep; NAASO, number of awakenings after sleep onset; s, subjective 
or self; SCT, symbol copying test; TST, total sleep time;   vAS-S, visual analog scale of sleepiness;   wASO, wake after sleep onset.Drug Design, Development and Therapy 2009:3 136
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study duration. Significant improvement in mean NAASO was 
noted in the active treatment groups compared to placebo at one 
month with mean values of 1.6 ± 0.1, 1.3 ± 0.1 (p  0.0001), 
and 1.1 ± 0.1 (p  0.0001) in the placebo, 10 mg, and 20 mg 
groups, respectively and significance was demonstrated for all 
three months. Sleep quality was significantly improved for all 
three months in the active treatment groups as well.
To date no published trials have directly compared the 
efficacy of indiplon to a FDA-approved agent for sleep. 
However, one trial examined next day effects using a five-
way crossover study in which adult patients received a single 
post-bedtime dose (four hours after lights-out) of indiplon IR 
10 mg, indiplon IR 20 mg, zolpidem 10 mg, zopiclone 7.5 mg, 
and placebo.26 The primary outcome was to evaluate next 
day effects of the medications compared to placebo using 
the VAS-S, DSST, and the SCT. No significant differences 
in the VAS-S, DSST, or SCT were noted four or six hours 
post dose in the indiplon 10 mg or 20 mg groups. Baseline 
VAS-S values were 47.4 ± 3 in the zolpidem 10 mg group, 
41.6 ± 3 in the zopiclone 7.5 mg group, and 48.1 ± 3.2 in the 
placebo group. Significant differences compared to placebo 
were noted in the VAS-S at four hours post-dose for zolpidem 
(60.5 ± 3; p = 0.042) and zopiclone (66.1 ± 3; p  0.0001) 
with this persisting to six hours post-dose in the zopiclone 
group (57.2 ± 3.1; p = 0.002).
elderly studies
Indiplon IR was specifically studied in elderly patients in four 
trials.18,26,32,33 Walsh and colleagues32 conducted a two-week 
study involving patients who met criteria for primary insom-
nia for at least three months comparing indiplon IR 5 mg or 
10 mg to placebo. End points were self-recorded in patient 
diaries. The mean LSO significantly improved at week 1 with 
a value of 34.6 ± 1.8 minutes (p  0.0001) in the 5 mg group 
and of 30.4 ± 1.6 minutes (p  0.0001) in the 10 mg group, 
compared to placebo with a value of 47.7 ± 2.5 minutes. This 
significant difference in mean LSO was maintained at week 
2 for both the 5 mg (p = 0.0160) and 10 mg (p = 0.0028) 
doses. Mean TST at week 1 was 312.2 ± 5 minutes in the 
placebo group, 340.3 ± 5 minutes (p  0.0001) in the 5 mg 
group, and 360 ± 5 minutes (p  0.0001) in the 10 mg group. 
TST remained significantly better at week 2 compared to 
placebo for the 5 mg (p = 0.0064) and 10 mg (p = 0.0015) 
doses. Significant improvement was also noted at week 1 for 
NAASO with values of  2 ± 0.1, 1.6 ± 0.1 (p = 0.0002), 1.4 ± 0.1 
(p  0.0001) in the placebo, 5 mg, and 10 mg groups, respec-
tively. At week 2, NAASO remained significant with values 
of 1.9 ± 0.1, 1.6 ± 0.1 (p = 0.0014), 1.5 ± 0.1 (p  0.0001) 
in the placebo, 5 mg, and 10 mg groups, respectively. The 
WASO was significant in the indiplon 10 mg group at week 
1 with 60.5 ± 4.1 minutes (p  0.0001) and week 2 with 
69.8 ± 4 minutes (p = 0.0112) compared to 83.3 ± 4.1 minutes 
at week 1 and 84.2 ± 4 minutes at week 2 in the placebo 
group. WASO was significant only in week 2 in the 5 mg 
group with values at week 1 of 73.1 ± 4 minutes (p = 0.0725) 
and week 2 with 70.8 ± 4 minutes (p = 0.0180). Sleep quality 
was also significantly improved in the 5 mg group at week 1 
(p  0.0001) and week 2 (p = 0.0007) as well as the 10 mg 
group at week 1 (p  0.0001) and week 2 (p = 0.005), 
compared to placebo.
The longest indiplon IR trial in the elderly was a six-month 
open-label extension trial. Patients with a three-month or 
more history of primary insomnia self-evaluated the benefit 
of indiplon on their insomnia.18 Patients received either 
indiplon IR 5 mg or 10 mg as needed at bedtime. Only 81 of 
121 patients completed six months of the study, with 72% of 
patients on the 5 mg dose and 92% of patients on the 10 mg 
dose reporting indiplon IR improved their insomnia.
Table 3 Clinical efficacy trials of indiplon MR in adults and elderly
Author (year) N Age range  
in years (Mean)
Duration Dose (mg) Outcomes
Jochelsona (2004)35 211 Nr (48) Two weeks indiplon 30, placebo ↑ sTSTb, ↓ LSO, ↓ swASO, ↓ 
sNAASO, ↑ sleep quality
Jochelsona (2003)36 36 19–42 (Nr) One night indiplon 40, placebo ↓ sLSO, ↑ sTST, ↑ sleep 
quality
Lydiard (2006)34 229 65–85 (71) Two weeks indiplon 15, placebo ↓ LSO, ↑ sTST, ↓ swASO, ↓ 
sNAASO, ↑ sleep quality
walsha (2003)37 60 Nr (69) Two nights indiplon 10, 20, 30, 35, 
placebo
↑ Se (20, 30, 35 mg only), ↓ 
LPS, ↓ wASO (20, 30, 35 mg 
only)
Notes: aAbstract-only data; bprimary endpoint.
Abbreviations: LSO, latency to sleep onset; LPS, latency to persistent sleep; NAASO, number of awakenings after sleep onset; NR, not reported; s, subjective; SE, sleep efficiency; 
TST, total sleep time; wASO, wake after sleep onset.Drug Design, Development and Therapy 2009:3 137
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The efficacy of indiplon IR was also examined in a 
four-period crossover study in elderly patients with a diagnosis 
of primary insomnia comparing indiplon IR 5 mg, 10 mg, or 
20 mg to placebo.33 PSG measured mean LPS was significantly 
improved with values of 13.8, 10.4, 9.8, and 25.2 minutes in 
the indiplon IR 5 mg, 10 mg, 20 mg, and placebo groups, 
respectively (p  0.001). Significant improvement in PSG 
measured mean TST was only demonstrated in the indiplon 
IR 10 mg group with a value of 372.1 minutes (p = 0.027) 
and in the 20 mg group with a value of 385.6 (p  0.001) 
minutes. TST values for the 5 mg and placebo groups 
were 363.7 and 354.4 minutes, respectively. Subjectively 
measured mean LSO was significantly improved with values 
of 28.8 minutes in the 5 mg group, 24.7 minutes in the 10 mg 
group, 20.2 minutes in the 20 mg group, and 41.8 minutes 
in the placebo group (p  0.004). No difference in next day 
residual effects as measured by DSST, SCT, and VAS-S was 
found in the indiplon groups compared to placebo.
Farber and colleagues26 studied indiplon IR in an indi-
rect manner with an approved comparative agent in elderly 
patients to evaluate next day residual effects. In a one-night, 
four-way crossover, single post-bedtime dose (four hours 
after lights-out) trial, indiplon IR 5 mg and 10 mg were com-
pared to placebo and zopiclone 3.75 mg as an active control. 
The primary outcome measured next day residual effects 
using the VAS-S, DSST, and the SCT. No significant dif-
ference in VAS-S or SCT was found in the medication arms 
versus placebo. Also, no significant difference was noted in 
the indiplon IR 5 mg group versus the placebo group in the 
DSST at four, six, or eight hours post-dose. However, the 
indiplon IR 10 mg group did demonstrate a significant differ-
ence at four hours post-dose compared to placebo (p = 0.022) 
in DSST, but no difference was noted at six and eight hours 
post-dose. Finally, zopiclone demonstrated a significant 
reduction in DSST at both four hours (p = 0.002) and eight 
hours (p = 0.003) post-dose compared to placebo.
indiplon Mr
Indiplon has also been studied in a MR form. The MR dosage 
form provides drug initially and then gradually releases 
medication providing therapeutic drug concentrations for an 
extended period during the night.34 It should be noted that 
study data related to indiplon MR is limited and three of the 
studies are only available in abstract form.35–37
Adult studies
A two-week study compared indiplon MR 30 mg to 
placebo in adults with a diagnosis of primary insomnia 
for greater than three months.35 LSO was 30 minutes in 
the indiplon MR group compared to 37 minutes in the 
placebo group (p = 0.0084) at week 1 and 27 minutes com-
pared to 33 minutes at week 2 (p = 0.0131), respectively. 
Subjective TST was significantly improved at week 1 
with 375 minutes in the indiplon MR group compared 
to 328 minutes in the placebo group (p  0.0001) 
and this continued at week 2 with 367 minutes in the 
indiplon MR group versus 336 minutes in the placebo 
group (p = 0.0013). Subjective WASO was significantly 
improved at 54 minutes compared to 79 minutes at week 
one (p  0.0001) and 51 minutes compared to 73 minutes 
at week 2 (p = 0.0003) in the indiplon MR and placebo 
groups, respectively. Sleep quality and NAASO were also 
significantly improved at weeks 1 and 2 (p  0.0001) 
compared to placebo (p-value not reported).
Table 4 Efficacy measures used in indiplon clinical trials38–40
Efficacy term Measured end 
point
Definition
Latency to sleep onset (LSO)* Sleep onset Time it takes to go from lying in bed to the beginning of sleep
Latency to persistent sleep (LPS) Sleep onset An objective PSG measurement of the time it takes to fall 
asleep and may also be defined as the first 10 minutes of 
continuous sleep
Total sleep time (TST)* Sleep duration Actual amount of sleep time which includes all stages of sleep 
(Stages 1–4 and reM sleep)
wake after sleep onset (wASO)* Sleep maintenance Amount of time spent awake after initial sleep onset until the 
end of the sleep cycle
Number of Awakenings after sleep onset (NAASO)* Sleep maintenance Number of times a subject awakens from sleep during the 
night
Sleep quality Overall efficacy Patient reported quality of sleep
Note: *Objectively measured by PSG or subjectively measured by patient diary or post-sleep questionnaires.
Abbreviations: PSG, polysomnogram; reM, rapid eye movement.Drug Design, Development and Therapy 2009:3 138
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Indiplon MR 40 mg was studied in healthy male 
volunteers compared to placebo in a venipuncture model of 
insomnia.36 Blood samples were taken throughout the night 
to impair sleep initiation and sleep maintenance. Subjectively 
measured improvements in LSO were noted in the indiplon 
MR group at 30.2 minutes versus 72.2 minutes in the placebo 
group (p  0.001). Significant improvement in subjective 
TST was found in the indiplon MR group with 315.6 minutes 
versus 246.6 minutes in the placebo group (p = 0.02). The 
NAASO was improved, but not significantly in the indiplon 
MR group compared to placebo and this lack of significance 
was believed to be due to the multiple blood draws during 
the night. Overall patient rated sleep quality was significantly 
improved compared to placebo (p = 0.04). No change in next 
day residual effects was noted compared to baseline using 
the DSST, SCT, and VAS-S assessments.
elderly studies
Indiplon MR 15 mg was studied in elderly patients with 
primary insomnia of at least three months duration in 
a two-week trial.34 All data was self-recorded by patients in 
daily sleep diaries. Significant improvement in mean sub-
jective TST occurred in the indiplon MR group at week 1 
with a value of 376 ± 4.2 minutes (p  0.0001) compared 
to the placebo group with a value of 327.5 ± 4.4 minutes. 
LSO was significantly improved in the indiplon group at 
weeks 1 and 2 with mean values of 22.0 ± 1.1 and 21.2 ± 
1.2 minutes (p  0.0001) compared to the placebo group 
at 34.9 ± 1.8 and 31 ± 1.8 minutes, respectively. Other 
significant findings at weeks 1 and 2 in the indiplon MR group 
included mean WASO with 55.7 ± 3.1 minutes at week 1 
(p  0.001) and 56.4 ± 3.6 minutes at week 2 (p  0.0001), 
compared to the placebo group at 84.9 ± 3.2 minutes at 
week 1 and 80.5 ± 3.7 minutes at week 2. Mean NAASO 
significantly improved in the indiplon MR group to 1.4 ± 0.1 
at week 1 (p  0.0001) and 1.3 ± 0.1 at week 2 (p  0.0001) 
compared to 2 ± 0.1 at week 1 and 1.9 ± 0.1 at week 2 in the 
placebo group. Sleep quality was also significantly improved 
in week 1 at 64% (p  0.0001) compared to 32% and in 
week 2 at 57% (p  0.002) compared to 35% in the indiplon 
MR and placebo groups, respectively. The authors did note 
that the study design may not completely represent elderly 
patients with chronic insomnia since patients with unstable 
medical or psychiatric illnesses were excluded and due to 
the strict time-in-bed requirements of the study.
Indiplon MR was examined in elderly patients comparing 
doses of 10 mg, 20 mg, 30 mg, and 35 mg to placebo with 
each patient receiving each dose of medication on two 
consecutive nights.37 Significant improvement in mean LPS 
values was found with values of 26 minutes in the placebo 
group, 17.6 minutes in the 10 mg group, 11.2 minutes 
in the 20 mg group, 11 minutes in the 30 mg group, and 
9.9 minutes in the 35 mg group (p  0.01). Mean sleep 
efficiency was significantly improved in the 20 mg, 30 mg, 
and 35 mg dosages only (p  0.0001). WASO in the placebo 
group was 103.2 minutes and 102.1 minutes in the 10 mg 
group (NS). Significant improvements in WASO occurred 
only in the 20 mg (87.3 minutes), 30 mg (81.9 minutes), and 
35 mg (83 minutes) dosage groups, compared to placebo 
(103.2 minutes) (p  0.01).
Safety and tolerability
Adult and elderly adverse events  
indiplon ir
The clinical studies reporting specific adverse events related 
to indiplon are summarized in Table 5.26,27,29,31,32,41 Other 
studies did not report details on adverse events but reported 
no serious adverse events.18,28,30,33 Based on available study 
data, no specific serious adverse events attributable to indip-
lon have been identified. Currently it is difficult to determine 
if there is a dose dependent increase in the incidence of spe-
cific adverse events. A 12-month randomized, double-blind, 
safety and tolerability study using as needed indiplon IR 
10 mg or 20 mg in 536 adults with insomnia found indiplon 
to be well tolerated without any dose dependent side effects.41 
However, a three-month study by Scharf and colleagues31 
reported discontinuation rates secondary to adverse events as 
higher in the indiplon 20 mg group (19.7%) compared to the 
indiplon 10 mg group (6.4%) and placebo (5.2%). Adverse 
events in this study were reported as transient, with median 
durations of 3–19 days for the adverse events occurring at 
a 5% incidence (see Table 5).
Indiplon’s safety in the elderly was specifically evalu-
ated in four studies,18,26,32,33 two of which are only available 
in abstract form.18,33 The largest of these studies evaluated 
two weeks of nightly use of indiplon IR 5 mg and 10 mg vs 
placebo in patients aged 65–80 years. A dose-related increase 
in study discontinuation due to adverse events was reported 
(8.4% on 10 mg, 5% on 5 mg, and 0.8% on placebo).32
rebound insomnia
The potential for rebound insomnia following indiplon 
discontinuation was examined in two adult studies28,31 and one 
elderly study.32 The first adult study found after three months 
of consecutive nightly use, rebound insomnia occurred Drug Design, Development and Therapy 2009:3 139
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on the first night in 22.1% of subjects on indiplon 20 mg, 
18.9% on indiplon 10 mg, and 8.8% on placebo; however, 
occurrence was much less on the second night, with rates of 
11.4%, 11.1%, and 1.1% of patients, respectively (no p value 
reported).31 In the second adult study, rebound insomnia, 
assessed subjectively and by PSG, was not found with indip-
lon after five weeks of use.28 In a two-week elderly study, 
rebound insomnia was noted the first night after stopping 
active treatment in 2% of the placebo group, 12.9% of the 
5 mg group (p = 0.004), and 8.6% (p  0.05) of the 10 mg 
group.32 These values decreased to 0%, 1.1%, and 1.1% in 
the placebo, 5 mg, and 10 mg groups, respectively on night 
2 after discontinuing therapy (NS).
withdrawal effects
The potential for indiplon to cause withdrawal effects was 
assessed in two adult studies28,31 and one elderly study32 using 
the Benzodiazepine Withdrawal Symptoms Questionnaire 
(BWSQ). The BWSQ uses a three-point severity scale with 
20 questions designed to evaluate withdrawal symptoms from 
medications that work at GABAA receptors.42 After three 
months of indiplon use, no discontinuation effects were seen 
in adults at the end of treatment and one week after stopping 
therapy.31 There was also no difference in discontinuation 
effects compared among the 10 mg and 20 mg groups in a 
five-week adult trial.28 Indiplon discontinuation following 
a two-week elderly study did not cause any withdrawal 
symptoms either.32
Abuse potential
The abuse potential of indiplon was studied using large doses 
of indiplon (30 mg, 50 mg, and 80 mg) versus placebo and 
triazolam (0.25 mg, 0.5 mg, and 0.75 mg) in 21 adult patients 
with a history of recreational substance abuse.43 Investigators 
Table 5 Clinical studies with reported ADr’s with indiplon ir greater than placebo
Author (year) ADRs Incidence (%) Specific ADR Incidence (%)
Placebo Indiplon 5 mg Indiplon 10 mg Indiplon 20 mg
Farber (2008)26 
elderly N = 36
Placebo 2.8  
indiplon 5 mg 2.8  
indiplon 10 mg 2.8
Headache 0 2.8 2.8 N/A
Farber (2008)26 
Adults N = 35
Placebo 8.6 
indiplon 10 mg 5.9  
indiplon 20 mg 11.8
Tiredness  
Headache  
retarded motor activity
0  
5.7  
0
N/A 0  
5.9  
0
2.9 
5.9 
2.9
roth (2007)27 
Adults N = 264
Placebo = 26  
indiplon 10 mg = 39 
indiplon 20 mg = 34
Headache  
Somnolence
2.3  
3.5
N/A 2.4  
6.0
6.7 
7.8
rosenberg (2007)29 
Adults N = 593
Placebo = 10  
indiplon 10 mg = 10.1 
indiplon 20 mg = 15.5
Headache  
Nausea
1  
0.5
N/A 2  
0.5
3.1 
2.1
Scharf (2007)31 
Adults N = 702
Not reported Uri  
Amnesia  
Dizziness  
Headache  
Somnolence
5.2  
0  
3  
6.9  
1.3
N/A 5.9  
1.3  
4.7  
8.5  
3
6  
6.4 
6.9  
9  
7.3
walsh (2007)32 
elderly N = 358
Placebo = 42  
indiplon 5 mg = 31.1 
indiplon 10 mg = 38.3
Headache  
Somnolence  
Depression  
Decreased appetite  
Dizziness  
Nausea
2.5  
0  
0  
0  
1.7  
0
7.5 
1.7  
5  
5.9  
4.2  
5
5.9  
5  
0  
0  
6.7  
1.7
N/A
Blacka (2006)41 
Adults N = 536
Not reported Headache  
Back pain  
Somnolence  
Uri  
Nasopharyngitis
11.8  
7.9  
7.9  
N/A  
N/A
8.7  
N/A  
N/A  
6.5  
5.9
Note: aAbstract-only data.
Abbreviations: ADr, adverse drug reaction; Uri, upper respiratory infection; N/A, not applicable.Drug Design, Development and Therapy 2009:3 140
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concluded that the abuse potential of indiplon at these high 
doses was not different when compared to triazolam; how-
ever, psychomotor and cognitive impairment might be less 
with indiplon versus triazolam.
Daytime residual effects
Studies evaluating daily and as needed use for up to 12 months 
in adults, and up to six months in the elderly, have found 
indiplon IR to be relatively safe,18,41 without complaints of 
next day residual effects.27,28,31,33 Details of these effects 
were previously described in the clinical trials section of 
this article.
Indiplon MR safety
The longest and largest study to date for the MR formulation 
investigated the use of indiplon MR 15 mg for two weeks in 
elderly patients.34 Forty-four percent of patients in the indip-
lon MR group had an adverse reaction compared to 28% in 
the placebo group, with 1% deemed severe. The following 
adverse events occurred at an incidence two-fold greater than 
placebo: dizziness (8%), headache (6%), and somnolence 
(4%). No falls were reported. There was evidence of rebound 
insomnia on the first night after discontinuation, but incidence 
returned to baseline by the second night. No evidence of 
withdrawal symptoms was found using the BWSQ. Safety 
data from the three other trials looking at the MR formula-
tion are only available in abstract form but report no serious 
adverse reactions.35–37
Dosing and administration
If granted FDA approval, it is anticipated that indiplon IR 
will be available in 5 mg and 10 mg strengths. It should be 
noted that efficacy studies in adults have used indiplon IR 
doses of 10 mg and 20 mg27,28,31 while efficacy studies in the 
elderly have used indiplon IR doses of 5 mg, 10 mg, and 
20 mg.18,32,33 Studies have assessed daily nighttime dosing, 
as needed dosing, and as needed post-bedtime dosing.
Contraindications, warnings,  
and precautions
Although labeling is not currently available, indiplon may not 
be an option for all patients. As with any medication, indiplon 
should be contraindicated in anyone with previous hypersen-
sitivity to this medication. In 2007 the FDA recommended 
a label change for sleep-inducing agents. This label change 
provided warnings regarding anaphylaxis, angioedema, and 
other “complex sleep-related behaviors which may include 
sleep-driving, making phone calls and preparing and eating 
food (while asleep)”.44 If approved, indiplon will likely 
receive the same warning. Because of its hepatic metabo-
lism, use should be avoided in those with impaired liver 
function. Alcohol use 5 drinks/day or 14 drinks/week 
was excluded in most trials; however, one study showed 
there was little or no interaction when indiplon IR 10 mg 
was co-administered with ethanol in 10 healthy patients.25 
Because indiplon acts centrally, concomitant alcohol use 
with indiplon should probably be avoided. Furthermore, 
most trials excluded concomitant use of centrally acting 
medications (anxiolytics, anticonvulsants, narcotics, antihis-
tamines). More studies are needed to determine if there would 
be any difference in the effectiveness or safety of indiplon 
when used with other centrally acting medications.
Benzodiazepine-like withdrawal symptoms were not 
reported after discontinuation of indiplon during clinical 
trials,28,31,32 however use should probably be avoided in 
those with previous dependence on other centrally acting 
medications, such as benzodiazepines or other hypnotics. 
One study in a small number of patients with a history of 
substance abuse found that the potential for abuse of large 
doses of indiplon was not different when compared with 
triazolam.43
Special populations
Indiplon IR and MR have been studied in patients aged 
18–80 years with lower doses in the elderly population. 
Neither the IR nor MR formulations have been studied in 
those 18 years of age or in pregnant women, therefore 
avoiding use of indiplon in these populations is warranted 
until more safety and efficacy data is available. Two of the 
three requirements identified in the 2007 FDA Approvable 
Letter included an objective/subjective clinical trial in the 
elderly and a pre-clinical study for use during the third 
trimester of pregnancy.10
Discussion
Indiplon may have several advantages to offer if approved 
for the treatment of primary insomnia. Indiplon IR appears 
safe and efficacious in the treatment of insomnia in both adult 
and elderly populations as demonstrated by improvements 
in LPS, LSO, TST, WASO, NAASO, and sleep quality. 
A potentially unique item to indiplon is post-bedtime 
dosing or middle of the night dosing.27 However, zaleplon 
has been used off label in a post-bedtime or middle of the 
night dosing method similar to indiplon.45 Indiplon appears 
to be well tolerated with no specific serious adverse events 
identified during clinical trials. However, the FDA has Drug Design, Development and Therapy 2009:3 141
indiplon in the management of insomnia Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
requested a study comparing adverse events of indiplon 
versus an FDA approved product for the treatment of 
primary insomnia.10
A potential issue related to indiplon in the treatment of 
primary insomnia is that the majority of adult studies used the 
10 mg and 20 mg dosages and the elderly studies used 5 mg 
and 10 mg dosages. FDA approval was sought only for the 
5 mg and 10 mg dosages. It is unclear if this will affect the 
potential efficacy in the adult population by seeking approval 
for only one of the dosages studied in adults. Based on avail-
able data, it does not appear the 5 mg dose was studied in 
adults. Also, it should be noted that at various time points in 
clinical studies, indiplon was unable to demonstrate statisti-
cal improvement in values such as TST, WASO, NAASO, 
and sleep quality depending on the dose of medication and 
the duration of the trial. Even though indiplon was studied 
specifically in the elderly, the FDA did request an additional 
safety and efficacy trial. Indiplon studies also excluded 
patients with current psychiatric illnesses and patients with 
acute medical illnesses which are two very common areas of 
use for sedative hypnotics. At the time of this writing, it is not 
known what specific indications indiplon will have or if it will 
have a specific advantage or indication over other products 
already approved for the treatment of primary insomnia. 
The post-bedtime or middle of the night dosing advantage 
of indiplon may be offset by the off label use of zaleplon in 
such a dosing method. Also, it is not known if indiplon will 
be indicated for sleep maintenance based on its short half-life. 
The MR formulation was investigated for that indication, 
however, indiplon MR received a Not Approvable Letter in 
2006 and it does not appear that its approval was pursued 
following that letter. From the current Approvable Letter it 
appears that sleep initiation or as needed post-bedtime dosing 
would be the primary indications for indiplon. Finally, the 
cost of indiplon is unknown and it is difficult to predict how 
insurance companies would view indiplon compared to other 
nonbenzodiazepine sedative hypnotics, some of which are 
available generically.
Conclusion
Indiplon IR appears safe and effective in the treatment of 
insomnia in both adult and elderly populations. Indiplon 
appears to be well tolerated with few side effects and no 
specific serious adverse events reported in clinical trials. 
Studies evaluating daily and as needed indiplon IR dosing 
did not reveal complaints of next day residual or withdrawal 
effects. The abuse potential of indiplon appears minimal, 
and it has a low, transient incidence of rebound insomnia. 
If FDA approved, indiplon may provide a unique dosing 
option for the treatment of insomnia related to post-bedtime 
or middle of the night dosing.
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